CHMP recommends six new drugs

The European Medicines Agency's committee has at its October meeting recommended six drugs for market approval in Europe. In addition, the authority recommends new uses for ten other drugs.

Patients with type 2 diabetes or atopic dermatitis are among those who will have more treatment options going foward.

During the monthly meeting of the EU Committee for Medicinal Products for Human Use (CHMP), which is responsible for preparing the Agency's opinions on future drugs, treatments for these diseases have seen their EU market approval recommended.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs